December 10, 2023

Secukinumab, a fully human monoclonal antibody that targets IL-17A, is a promising treatment option in pediatric patients aged 6 years and above with moderate to severe plaque psoriasis. Psoriasis is a chronic and inflammatory skin disease that affects 1% to 5% of the global population. It is caused by T-cell activity and genetic and epigenetic...

Phototherapy is a promising treatment option for various skin conditions, but further research is needed to explore its full potential and safety. Non-invasive phototherapy using LED technology is becoming popular for medical and aesthetic dermatological conditions. Studies have shown that these treatments can promote wound healing and reduce inflammation. Recent studies using blue light have...